Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis (MIDALS)
Primary Purpose
Amyotrophic Lateral Sclerosis With Dementia
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Whole Body MRI and ENMG
Sponsored by
About this trial
This is an interventional diagnostic trial for Amyotrophic Lateral Sclerosis With Dementia focused on measuring Amyotrophic, Sclerosis
Eligibility Criteria
Inclusion Criteria:
- Consent form signed by the patient
- Patients suspected ALS defined according Awaji Shima criteria (possible, probable, defined)
- Clinical assessment of upper motor neuron involvement
- Electrophysiologic assessment of lower motor neuron involvement
Exclusion Criteria:
- inability to give informed consent
- a contraindication to MRI
- respiratory failure impairing ability to lie flat in the scanner.
- Patient placed under judicial protection or under another protective regime,
- Females who are pregnant
Sites / Locations
- Pascal CINTASRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
ENMG and muscle analyses on whole body muscles MRI.
Arm Description
Diffusion of active and chronic muscle denervation will be assessed on ENMG and whole body muscle MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria
Outcomes
Primary Outcome Measures
Diagnostic certainty 1.ENMG according to El Escorial revised criteria using ENMG alone, MRI alone and ENMG+MRI to define denervation diffusion
number of patients classified as possible, probable or certain according to El Escorial criteria using ENMG alone, IMR alone and ENMR+MRI
Secondary Outcome Measures
Define precise topographic and characteristic of muscle involvement in ALS by MRI
number of patients with concordance between ENMG and MRI for the detection of denervation
Full Information
NCT ID
NCT04868994
First Posted
March 26, 2021
Last Updated
July 10, 2023
Sponsor
University Hospital, Toulouse
1. Study Identification
Unique Protocol Identification Number
NCT04868994
Brief Title
Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis
Acronym
MIDALS
Official Title
Contribution of Whole Body Muscle MRI for Early Diagnosis of Amyotrophic Lateral Sclerosis.
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2021 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Toulouse
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Nearly 60% of Amyotrophic Lateral Sclerosis (ALS) patients have a low level of diagnostic certainty (possible, probable) at the time of diagnosis. In the absence of biomarkers, this diagnosis is based, among other things, on the demonstration of the diffusion of signs of denervation by electroneuromyography (ENMG). The objective of this study is to improve the earliness and the level of diagnostic certainty by better demonstrating the diffusion of the denervation process by whole body muscular MRI.
Detailed Description
The objective of this study is to show that the combination of ENMG and whole body muscle MRI (WB-MRI) can increase the diagnosis of definite ALS at the onset of the disease For 50 consecutive patients with suspected ALS, the present study will prospectively perform needle electromyography (EMG) and muscle analyses on whole body MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria. On whole body MRI acquisition, for 83 muscles, will be explored fatty infiltration and atrophy on fat images (chronic denervation) and muscle edema on water images (acute denervation). EMG studies will be performed in at least 10 muscles (tongue, biceps brachii, first dorsalis interosseous, T10 paraspinalis, vastus lateralis, and tibialis anterior). Diagnostic classification according EMG and/ or MRI abnormalities in bulbar and the 3 spinal regions will be compared independently.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amyotrophic Lateral Sclerosis With Dementia
Keywords
Amyotrophic, Sclerosis
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
ENMG and muscle analyses on whole body muscles MRI.
Arm Type
Experimental
Arm Description
Diffusion of active and chronic muscle denervation will be assessed on ENMG and whole body muscle MRI. The diagnostic category will be determined by revised El Escorial criteria and Awaji criteria
Intervention Type
Diagnostic Test
Intervention Name(s)
Whole Body MRI and ENMG
Intervention Description
Whole body muscle MRI lasting 30 to 45 min without injection of contrast medium an ENMG
Primary Outcome Measure Information:
Title
Diagnostic certainty 1.ENMG according to El Escorial revised criteria using ENMG alone, MRI alone and ENMG+MRI to define denervation diffusion
Description
number of patients classified as possible, probable or certain according to El Escorial criteria using ENMG alone, IMR alone and ENMR+MRI
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Define precise topographic and characteristic of muscle involvement in ALS by MRI
Description
number of patients with concordance between ENMG and MRI for the detection of denervation
Time Frame
1 month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Consent form signed by the patient
Patients suspected ALS defined according Awaji Shima criteria (possible, probable, defined)
Clinical assessment of upper motor neuron involvement
Electrophysiologic assessment of lower motor neuron involvement
Exclusion Criteria:
inability to give informed consent
a contraindication to MRI
respiratory failure impairing ability to lie flat in the scanner.
Patient placed under judicial protection or under another protective regime,
Females who are pregnant
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pascal CINTAS, MD PHD
Phone
05 61 77 94 40
Email
cintas.p@chu-toulouse.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Anne Cecile Coville
Phone
(05345) 58700
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pascal CINTAS, MD
Organizational Affiliation
University Hospital, Toulouse
Official's Role
Principal Investigator
Facility Information:
Facility Name
Pascal CINTAS
City
Toulouse
ZIP/Postal Code
31000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pascal CINTAS, MD PHD
Phone
0561779440
Email
cintas.p@chu-toulouse.fr
First Name & Middle Initial & Last Name & Degree
Anne Cecile Coville
Phone
0534558700
12. IPD Sharing Statement
Learn more about this trial
Magnetic Imaging for Diagnostic of Amyotrophic Lateral Sclerosis
We'll reach out to this number within 24 hrs